ProBioGen and Chiome in Antibody Manufacturing Deal

Article

Under an agreement, ProBioGen will develop a stable cell-line for and manufacture an anti-cancer antibody for Chiome using its proprietary cancer cell-killing technology.

ProBioGen, a service and technology provider for complex therapeutic glycoproteins, announced on Oct. 5, 2017 that it signed a service and license agreement with Chiome Bioscience, a Japanese antibody discovery and development company, to use ProBioGen’s cancer cell-killing technology, GlymaxX, for a clinical candidate in an antibody manufacturing program for Chiome.

Specifically, ProBioGen will develop a stable GlymaxX cell line and then will conduct process development and GMP manufacturing of the antibody, which is derived from antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced cancer stem cells. The antibody will be optimized for cancer cell-killing activity.

Dr. Koji Nakamura, head of drug discovery laboratories and former CEO of LivTech, an R&D and antibody drug discovery company acquired by Chiome in December 2013, explained in a company press release: “We have tested ProBioGen’s GlymaxX technology for our antibody before and saw in-vivo in animal models an obviously potentiated cancer cell-killing efficacy of its afucosylated version. This, together with our long-standing relationship with the ProBioGen team, the company’s demonstrated track record in developing stable cell lines up to reliable GMP manufacturing for small and big biotechs, and the favorable, royalty-free commercial GlymaxX Terms, made our selection quite simple.”

“We look much forward to a productive partnership which combines Chiome’s outstanding antibody drug candidate, LIV-1205, with our own antibody development expertise and our GlymaxX ADCC enhancement technology to make together with Chiome a marked contribution to combat various cancers,” said ProBioGen’s CEO Wieland Wolf in the release.

Source: ProBioGen

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Related Content
© 2025 MJH Life Sciences

All rights reserved.